Development of neutralizing monoclonal antibodics against the 'spike' protein of SARS-CoV-2

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:1 publications

Grant number: 01KI2040

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $206,779.34
  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

    Pending
  • Research Location

    Germany, Europe
  • Lead Research Institution

    Helmholtz Zentrum München
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

discovery - We engineer extracellular vesicles (eEVs) as antigen carriers to encompass complex membrane proteins in their correct conformation. Conformational authenticity of functional antigenic domains determines the quality of immune responses. Thus, when injected into animals such eEVs can give rise to functional antibodies with superb affinity and avidity. Here, we propose to use eEVs for the systematic generation of a panel of neutralizing antibodies directed against the surface 'spike' glycoprotein of SARS-CoV-2, which is considered central to the entry and fusion of this virus with all its target cells. Using the eEV approach, we also developed a virus-free platform technology that will support the functional screening of SARS-CoV-2 neutralizing antibodies. With this novel assay we will functionally validate the different classes of antibodies obtained from immunizations with eEVs, screen for distinct neutralizing antibodies, characterize them, and humanize and express the most promising clinical candidate in CHO cells for its further preclinical evaluation with a drug target profile to prevent or curb COVID-19 infection.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test.